{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T05:28:18Z","timestamp":1767331698147,"version":"3.48.0"},"reference-count":46,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T00:00:00Z","timestamp":1767312000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Graves\u2019 hyperthyroidism (GH) presents significant challenges in optimizing Iodine-131 (I-131) therapy, largely due to the variability in patient responses and the limitations of traditional dosing methods. This study aimed to develop and validate a Random Forest Regressor (RFR) model to predict the effective total iodine dose (TID) necessary to achieve remission in patients with GH, thereby enhancing precision and individualization in patient management.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A retrospective cohort study design was employed, analyzing comprehensive clinical data from 975 adult GH patients who achieved remission and underwent\n                      <jats:sup>131<\/jats:sup>\n                      I therapy 25 January 2015 and 8 August 2023. The cohort, consisting of 975 patients, was divided into a development set (n = 633, spanning from 25 January 2015 to 25 January 2021) and a temporal validation set (n = 342, covering the period from 26 January 2021 to 8 August 2023). A RFR model was developed, utilizing variables such as gender, iodine dose per gram of thyroid tissue (IDPG), Free Thyroxine (FT4), 24-hour Radioactive Iodine Uptake (RAIU24h), Effective half-life (Teff), and thyroid weight to predict the TID. The model\u2019s interpretability was further enhanced using SHapley Additive exPlanations (SHAP) values.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Key predictive variables identified through LASSO-Gaussian regression analysis were gender, IDPG, FT4, RAIU24h, Teff, and thyroid weight. The RFR model demonstrated strong predictive performance, achieving an R-squared value of 0.858 \u00b1 0.05 on the validation set and 0.838 on the temporal validation set, indicating its high capability to explain the variance in TID. SHAP analysis provided crucial insights into the contribution of each feature, highlighting, for example, that high FT4, Teff, and thyroid weight were primary positive contributors to the predicted TID, while RAIU24h offered a compensatory negative contribution.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      In conclusion, this study successfully developed and validated an RFR model that accurately predicts the TID for GH patients achieved remission. By integrating multi-dimensional features and providing interpretability through SHAP values, this model offers a sophisticated approach to dose personalization. This advancement has the potential to significantly improve\n                      <jats:sup>131<\/jats:sup>\n                      I treatment efficacy, minimize adverse effects such as hypothyroidism, and foster more precise, individualized patient care in GH.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2025.1729926","type":"journal-article","created":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T05:24:32Z","timestamp":1767331472000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Prediction of total iodine dose of I-131 therapy for Graves\u2019 hyperthyroidism achieved remission status: a random forest regressor model approach to assess treatment efficacy"],"prefix":"10.3389","volume":"16","author":[{"given":"Lu","family":"Lu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongyun","family":"Meng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaojuan","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaozhou","family":"Mo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zeyong","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fengyang","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuehua","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kehua","family":"Liao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wentan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.19052","article-title":"Hyperthyroidism: A review","volume":"330","author":"Lee","year":"2023","journal-title":"JAMA"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.5603\/EP.a2021.0092","article-title":"Definitive treatment of Graves\u2019 disease in children and adolescents","volume":"72","author":"Kr\u00f3l","year":"2021","journal-title":"Endokrynol Pol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(23)00005-0","article-title":"Hyperthyroidism: aetiology, pathogenesis, diagnosis, management, complications, and prognosis","volume":"11","author":"Wiersinga","year":"2023","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-07-0205","article-title":"Psychological implications of Graves\u2019 orbitopathy","volume":"157","author":"Coulter","year":"2007","journal-title":"Eur J Endocrinol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-12-0627","article-title":"Mechanisms in endocrinology: Heart failure and thyroid dysfunction","volume":"167","author":"Biondi","year":"2012","journal-title":"Eur J Endocrinol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-4184","article-title":"Subclinical and overt thyroid dysfunction and risk of all-cause mortality and cardiovascular events: a large population study","volume":"99","author":"Selmer","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.112.105148","article-title":"The SNMMI practice guideline for therapy of thyroid disease with 131I 3.0","volume":"53","author":"Silberstein","year":"2012","journal-title":"J Nucl Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1080\/09553002.2019.1665206","article-title":"The effect of radioiodine treatment on the diseased thyroid gland","volume":"95","author":"Riley","year":"2019","journal-title":"Int J Radiat Biol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"29","DOI":"10.2147\/tcrm.s5229","article-title":"Current and emerging treatment options for Graves\u2019 hyperthyroidism","volume":"6","author":"Abraham","year":"2010","journal-title":"Ther Clin Risk Manag"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2796.1994.tb00837.x","article-title":"Standardized radioiodine therapy in Graves\u2019 disease: the persistent effect of thyroid weight and radioiodine uptake on outcome","volume":"236","author":"de Bruin","year":"1994","journal-title":"J Intern Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1159\/000507018","article-title":"Variability of thyroid measurements from ultrasound and laboratory in a repeated measurements study","volume":"10","author":"Ittermann","year":"2021","journal-title":"Eur Thyroid J"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1210\/er.2012-1030","article-title":"Radioiodine therapy in benign thyroid diseases: effects, side effects, and factors affecting therapeutic outcome","volume":"33","author":"Bonnema","year":"2012","journal-title":"Endocr Rev"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-023-06274-5","article-title":"The EANM guideline on radioiodine therapy of benign thyroid disease","volume":"50","author":"Campenn\u00ec","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.243170","article-title":"The role of nuclear medicine in the clinical management of benign thyroid disorders, part 1: hyperthyroidism","volume":"62","author":"Mariani","year":"2021","journal-title":"J Nucl Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1959.00270060076010","article-title":"Radioiodine therapy of hyperthyroidism","volume":"103","author":"Sheline","year":"1959","journal-title":"AMA Arch Intern Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1136\/svn-2017-000101","article-title":"Artificial intelligence in healthcare: past, present and future","volume":"2","author":"Jiang","year":"2017","journal-title":"Stroke Vasc Neurol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1023\/A:1010933404324","article-title":"Random forests","volume":"45","author":"Breiman","year":"2001","journal-title":"Mach Learn"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/widm.1072","article-title":"Overview of random forest methodology and practical guidance with emphasis on computational biology and bioinformatics","volume":"2","author":"Boulesteix","year":"2012","journal-title":"Wiley Int. Rev. Data Min. and Knowl. Disc."},{"key":"B19","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.jvir.2022.11.004","article-title":"Prediction of response of hepatocellular carcinoma to radioembolization: machine learning using preprocedural clinical factors and MR imaging radiomics","volume":"34","author":"\u0130nce","year":"2023","journal-title":"J Vasc Interventional Radiol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"7402","DOI":"10.1038\/s41598-017-07408-0","article-title":"Machine learning applications for prediction of relapse in childhood acute lymphoblastic leukemia","volume":"7","author":"Pan","year":"2017","journal-title":"Sci Rep"},{"key":"B21","doi-asserted-by":"publisher","first-page":"e10212","DOI":"10.2196\/10212","article-title":"Prediction of glucose metabolism disorder risk using a machine learning algorithm: pilot study","volume":"3","author":"Maeta","year":"2018","journal-title":"JMIR Diabetes"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btr597","article-title":"MissForest\u2014non-parametric missing value imputation for mixed-type data","volume":"28","author":"Stekhoven","year":"2012","journal-title":"Bioinformatics"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1900654116","article-title":"Definitions, methods, and applications in interpretable machine learning","volume":"116","author":"Murdoch","year":"2019","journal-title":"Proc Natl Acad Sci"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s00521-019-04051-w","article-title":"The importance of interpretability and visualization in machine learning for applications in medicine and health care","volume":"32","author":"Vellido","year":"2020","journal-title":"Neural Comput Applic"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/coin.12410","article-title":"Interpretability in healthcare: A comparative study of local machine learning interpretability techniques","volume":"37","author":"ElShawi","year":"2021","journal-title":"Computational Intelligence"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1109\/ACCESS.2023.3321509","article-title":"Assessment of hematological predictors via explainable artificial intelligence in the prediction of acute myocardial infarction","volume":"11","author":"Yilmaz","year":"2023","journal-title":"IEEE Access"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2016.0229","article-title":"2016 American thyroid association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis","volume":"26","author":"Ross","year":"2016","journal-title":"Thyroid"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3390\/tomography11010002","article-title":"Effective dose estimation in computed tomography by machine learning","volume":"11","author":"Ferrante","year":"2025","journal-title":"Tomography"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1109\/ACCESS.2024.3464866","article-title":"Predictive analysis of network-based attacks by hybrid machine learning algorithms utilizing bayesian optimization, logistic regression, and random forest algorithm","volume":"12","author":"Sannigrahi","year":"2024","journal-title":"IEEE Access"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.4183\/aeb.2020.329","article-title":"A new simple, personalized, and quantitative empirical method for determining 131I activity in treating graves\u2019 Disease","volume":"16","author":"Xu","year":"2020","journal-title":"Acta Endo (Buc)"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.33192\/Smj.2021.15","article-title":"Success rate of radioactive iodine therapy in graves\u2019 Disease using dose corrected for thyroid gland size","volume":"72","author":"Raruenrom","year":"2021","journal-title":"Smj"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1967\/s002449912470","article-title":"Predictive factors for the efficacy of 131I therapy with formulated dosage calculation on Graves\u2019 disease","volume":"25","author":"Zheng","year":"2022","journal-title":"Hell J Nucl Med"},{"key":"B33","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1097\/TP.0000000000002923","article-title":"Seeing the forest for the trees: random forest models for predicting survival in kidney transplant recipients","volume":"104","author":"Sapir-Pichhadze","year":"2020","journal-title":"Transplantation"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-938232\/v1","article-title":"Prediction of 131i therapeutic dose and prognosis in hyperthyroidism patients using mechanical learning model","author":"Gao","year":"2021"},{"key":"B35","doi-asserted-by":"publisher","first-page":"e220119","DOI":"10.1530\/EC-22-0119","article-title":"Machine learning identifies baseline clinical features that predict early hypothyroidism in patients with Graves\u2019 disease after radioiodine therapy","volume":"11","author":"Duan","year":"2022","journal-title":"Endocrine Connections"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyad252","article-title":"Random forest for predicting treatment response to radioiodine and thyrotropin suppression therapy in patients with differentiated thyroid cancer but without structural disease","volume":"29","author":"Sa","year":"2024","journal-title":"Oncologist"},{"key":"B37","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1097\/MNM.0000000000000770","article-title":"Prognostic factor analysis in 325 patients with Graves\u2019 disease treated with radioiodine therapy","volume":"39","author":"Yang","year":"2018","journal-title":"Nucl Med Commun"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1097\/MNM.0000000000000285","article-title":"Factors influencing the success of radioiodine therapy in patients with Graves\u2019 disease","volume":"36","author":"\u0160filigoj","year":"2015","journal-title":"Nucl Med Commun"},{"key":"B39","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1967\/s002449912554","article-title":"Effect tracking of 131I treatment in Graves\u2019 hyperthyroidism patients within 1 year and analysis of the factors that may influence the cure","volume":"26","author":"Zhao","year":"2023","journal-title":"Hell J Nucl Med"},{"key":"B40","doi-asserted-by":"publisher","first-page":"7535093","DOI":"10.1155\/2024\/7535093","article-title":"Predictive factors for the efficacy of radioactive iodine treatment of graves\u2019 Disease","volume":"2024","author":"Feng","year":"2024","journal-title":"Int J Endocrinol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjsurg.2021.03.068","article-title":"Predictive factors of radioiodine therapy failure in Graves\u2019 Disease: A meta-analysis","volume":"223","author":"Shalaby","year":"2022","journal-title":"Am J Surg"},{"key":"B42","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s12902-020-00551-2","article-title":"Predictors of euthyreosis in hyperthyroid patients treated with radioiodine 131I\u2013: a retrospective study","volume":"20","author":"Stachura","year":"2020","journal-title":"BMC Endocr Disord"},{"key":"B43","doi-asserted-by":"publisher","first-page":"31148","DOI":"10.1038\/s41598-024-82521-5","article-title":"Predictive factors influencing hypothyroidism following the radioactive iodine treatment of Graves\u2019 disease in different periods","volume":"14","author":"Zhao","year":"2024","journal-title":"Sci Rep"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1007\/s12149-023-01891-4","article-title":"Factors predicting remission in hyperthyroid patients after low-dose I-131 therapy: 20 years retrospective study from a tertiary care hospital","volume":"38","author":"SY","year":"2024","journal-title":"Ann Nucl Med"},{"key":"B45","doi-asserted-by":"publisher","first-page":"BSR20191609","DOI":"10.1042\/BSR20191609","article-title":"Predictive factors for the outcomes of Graves\u2019 disease patients with radioactive iodine (131I) treatment","volume":"40","author":"Xing","year":"2020","journal-title":"Biosci Rep."},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.20849","article-title":"Prediction of thyroidal 131 I effective half-life in patients with Graves\u2019 disease","volume":"8","author":"Zhang","year":"2017","journal-title":"Oncotarget"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1729926\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T05:24:33Z","timestamp":1767331473000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1729926\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,2]]},"references-count":46,"alternative-id":["10.3389\/fendo.2025.1729926"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2025.1729926","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,2]]},"article-number":"1729926"}}